Data from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Authors: Geng Huimin , Brennan Sarah , Milne Thomas A. , Chen Wei-Yi , Li Yushan , Hurtz Christian , Kweon Soo-Mi , Zickl Lynette , Shojaee Seyedmehdi , Neuberg Donna , Huang Chuanxin , Biswas Debabrata , Xin Yuan , Racevskis Janis , Ketterling Rhett P. , Luger Selina M. , Lazarus Hillard , Tallman Martin S. , Rowe Jacob M. , Litzow Mark R. , Guzman Monica L. , Allis C. David , Roeder Robert G. , Müschen Markus , Paietta Elisabeth , Elemento Olivier , Melnick Ari M. 
Published: March 2024

<div>Abstract<p>Genetic lesions such as <i>BCR–ABL1</i>, <i>E2A–PBX1</i>, and <i>MLL</i> rearrangements (<i>MLLr</i>) are associated with unfavorable outcomes in adult B-cell precursor acute lymphoblastic leukemia (B-ALL). Leukemia oncoproteins may directly or indirectly disrupt cytosine methylation patterning to mediate the malignant phenotype. We postulated that DNA methylation signatures in these aggressive B-ALLs would point toward disease mechanisms and useful biomarkers and therapeutic targets. We therefore conducted DNA methylation and gene expression profiling on a cohort of 215 adult patients with B-ALL enrolled in a single phase III clinical trial (ECOG E2993) and normal control B cells. In <i>BCR–ABL1</i>-positive B-ALLs, aberrant cytosine methylation patterning centered around a cytokine network defined by hypomethylation and overexpression of <i>IL2RA</i>(CD25). The E2993 trial clinical data showed that CD25 expression was strongly associated with a poor outcome in patients with ALL regardless of <i>BCR–ABL1</i> status, suggesting CD25 as a novel prognostic biomarker for risk stratification in B-ALLs. In <i>E2A</i>–<i>PBX1</i>-positive B-ALLs, aberrant DNA methylation patterning was strongly associated with direct fusion protein binding as shown by the E2A–PBX1 chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq), suggesting that E2A–PBX1 fusion protein directly remodels the epigenome to impose an aggressive B-ALL phenotype. <i>MLL</i>r B-ALL featured prominent cytosine hypomethylation, which was linked with MLL fusion protein binding, H3K79 dimethylation, and transcriptional upregulation, affecting a set of known and newly identified MLL fusion direct targets with oncogenic activity such as <i>FLT3</i> and <i>BCL6</i>. Notably, BCL6 blockade or loss of function suppressed proliferation and survival of <i>MLL</i>r leukemia cells, suggesting BCL6-targeted therapy as a new therapeutic strategy for <i>MLL</i>r B-ALLs.</p><p><b>Significance:</b> We conducted the first integrative epigenomic study in adult B-ALLs, as a correlative study to the ECOG E2993 phase III clinical trial. This study links for the first time the direct actions of oncogenic fusion proteins with disruption of epigenetic regulation mediated by cytosine methylation. We identify a novel clinically actionable biomarker in B-ALLs: <i>IL2RA</i>(CD25), which is linked with BCR–ABL1 and an inflammatory signaling network associated with chemotherapy resistance. We show that BCL6 is a novel MLL fusion protein target that is required to maintain the proliferation and survival of primary human adult MLLr cells and provide the basis for a clinical trial with BCL6 inhibitors for patients with MLLr. <i>Cancer Discov; 2(11); 1004–23. ©2012 AACR.</i></p><p>Read the Commentary on this article by Cimmino and Aifantis, p. 976.</p><p>This article is highlighted in the In This Issue feature, p. 961</p></div>